PARSIPPANY, N.J., June 8, 2026
Onkos Surgical announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the application of its NanoCept® Antibacterial Technology to titanium implants within the ELEOS™ Limb Salvage System. The clearance expands the availability of NanoCept-coated implants across a broader range of orthopedic oncology and limb reconstruction procedures. The approval marks the second FDA 510(k) clearance for NanoCept since its original De Novo authorization and follows the October 2025 clearance of the ELEOS Proximal Tibia with NanoCept technology.
FDA Clearance Expands Access to Antibacterial Implant Technology
The newly cleared indication allows NanoCept Antibacterial Technology to be applied to titanium implants used within the ELEOS Limb Salvage System. NanoCept-coated implants are designed to support patients undergoing complex orthopedic oncology and revision procedures, where risks associated with bacterial contamination may be elevated due to patient-specific and procedural factors. By extending the technology to titanium implants, surgeons now have access to antibacterial surface protection across a wider portion of the ELEOS reconstruction platform.
Preclinical Data Demonstrates Broad Antibacterial Activity
According to Onkos Surgical, NanoCept Antibacterial Technology is supported by extensive preclinical testing that demonstrated reduction of bacteria commonly encountered in surgical environments. The technology showed activity against organisms including Staphylococcus aureus (MRSA and MSSA), Cutibacterium acnes, Escherichia coli, and Pseudomonas aeruginosa. The antibacterial surface is intended to address bacterial contamination on implant surfaces before implantation. However, the company noted that NanoCept’s effectiveness in preventing or reducing infection rates has not yet been demonstrated in human clinical trials.
Advertisement
Strengthening Solutions for Complex Orthopedic Reconstruction
The FDA clearance represents a significant milestone for Onkos Surgical as it continues expanding advanced technologies for musculoskeletal oncology and complex orthopedic reconstruction. The company stated that integrating NanoCept onto titanium implants commonly used in limb salvage procedures provides surgeons with an additional tool when treating challenging cases requiring extensive reconstruction. Onkos Surgical believes the broader availability of NanoCept technology will further support personalized treatment approaches and improve surgical options for patients undergoing limb reconstruction and tumor-related orthopedic procedures.
Source: Onkos Surgical press release
